8.38

13.34% -1.29

After Hours: 8.17 -0.21 -2.51%

Forte Biosciences Inc (FBRX)

Overview News Price History Option Chain Financials Discussions Forecast

Forte Biosciences Inc stock is traded at $8.38, with a volume of 46,467. It is down -13.34% in the last 24 hours and up +14.12% over the past month. Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).

Previous Close:

$9.67

Open:

$9.66

24h Volume:

46,467

Relative Volume:

1.00

Market Cap:

$55.14M

Revenue:

Net Income/Loss:

$-31.48M

P/E Ratio:

-8.0577

EPS:

-1.04

Net Cash Flow:

$-28.71M

1W Performance:

+11.44%

1M Performance:

+14.12%

6M Performance:

-61.40%

1Y Performance:

-45.05%

1-Day Range:

$8.25

$9.66

1-Week Range:

$7.84

$13.84

52-Week Range:

$4.11

$28.68

Forte Biosciences Inc Stock (FBRX) Company Profile

Name

Forte Biosciences Inc

Sector

Healthcare (1177)

Industry

Biotechnology (671)

Phone

(310) 618-6994

Address

3060 PEGASUS PARK DRIVE, DALLAS, CA

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

FBRX's Discussions on Twitter

Compare FBRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FBRX Forte Biosciences Inc	8.38	49.51M	0	-31.48M	-28.71M	-1.04
ONC Beone Medicines Ltd Adr	246.68	25.81B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	447.09	111.46B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.30	40.37M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	605.39	64.44B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	77.49	6.19B	0	-153.72M	-103.81M	-2.00

Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-21-25	Initiated	TD Cowen	Buy
Apr-08-24	Upgrade	Ladenburg Thalmann	Neutral → Buy
Sep-20-21	Upgrade	Chardan Capital Markets	Sell → Buy
Sep-03-21	Downgrade	B. Riley Securities	Buy → Neutral
Sep-03-21	Downgrade	Chardan Capital Markets	Buy → Sell
Sep-03-21	Downgrade	Ladenburg Thalmann	Buy → Neutral
Sep-03-21	Downgrade	Truist	Buy → Hold
May-14-21	Initiated	B. Riley Securities	Buy
Mar-26-21	Initiated	Citigroup	Buy
Aug-28-20	Upgrade	Chardan Capital Markets	Neutral → Buy
Aug-25-20	Initiated	Truist	Buy

View All

Forte Biosciences Inc Stock (FBRX) Latest News

02:34 AM

Forte Biosciences Sees Unusually High Options Volume (NASDAQ:FBRX) - Defense World

02:34 AM

May 28, 2025

How the (FBRX) price action is used to our Advantage - news.stocktradersdaily.com

May 28, 2025

Forte Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 15, 2025

Forte Biosciences Q1 Operating Expenses USD 16.124 Million - marketscreener.com

May 15, 2025

Forte Biosciences (FBRX) Advances Trials for FB102 in Celiac Disease and Vitiligo | FBRX Stock News - GuruFocus

May 15, 2025

Forte Biosciences reports Q1 EPS ($1.37), consensus (95c) - TipRanks

May 15, 2025

Forte Biosciences, Inc. Announces Results and Provides Update - Eagle-Tribune

May 15, 2025

Forte Biosciences Q1: Celiac Disease Trial Results Imminent, New Vitiligo Study Launches - Stock Titan

May 15, 2025

Stock Traders Buy High Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - Defense World

May 15, 2025

May 10, 2025

Forte Biosciences (FBRX) Expected to Announce Earnings on Monday - Defense World

May 10, 2025

May 08, 2025

JPMorgan Chase & Co. Trims Stock Holdings in Alto Neuroscience, Inc. (NYSE:ANRO) - Defense World

May 08, 2025

Royal Bank of Canada Has Lowered Expectations for Zimmer Biomet (NYSE:ZBH) Stock Price - Defense World

May 08, 2025

JPMorgan Chase & Co. Buys New Holdings in Innovator U.S. Equity Accelerated ETF – January (BATS:XDJA) - Defense World

May 08, 2025

(FBRX) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

May 08, 2025

May 03, 2025

Geode Capital Management LLC Boosts Stock Position in AmpliTech Group, Inc. (NASDAQ:AMPG) - Defense World

May 03, 2025

Geode Capital Management LLC Increases Position in Forte Biosciences, Inc. (NASDAQ:FBRX) - Defense World

May 03, 2025

Geode Capital Management LLC Increases Position in Lexaria Bioscience Corp. (NASDAQ:LEXX) - Defense World

May 03, 2025

May 01, 2025

Alopecia Areata Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Corp - Barchart.com

May 01, 2025

Meta Doubles Down on AI: Is the Stock Ready to Skyrocket? - The Globe and Mail

May 01, 2025

Apr 19, 2025

Shining a Light on IL-13: Optimizing Moderate-to-Severe Atopic Dermatitis Treatment in Daily Practice - Healio

Apr 19, 2025

Apr 18, 2025

Forte Biosciences sets Annual Meeting for May 29 By Investing.com - Investing.com Canada

Apr 18, 2025

Forte Biosciences sets Annual Meeting for May 29 - Investing.com Australia

Apr 18, 2025

Traders Buy High Volume of Call Options on Forte Biosciences (NASDAQ:FBRX) - Defense World

Apr 18, 2025

Apr 17, 2025

Mr. Ethan Billings recommends paying close attention to biotech stocks - FinancialContent

Apr 17, 2025

Apr 15, 2025

Profit from Trump’s Tariff Playbook with TipRanks’ New Comparison Tool - The Globe and Mail

Apr 15, 2025

Apr 13, 2025

Nvidia and Broadcom Helped Propel This ETF 18% Higher in a Single Day. Here's Why It's Still a Buy Now. - The Globe and Mail

Apr 13, 2025

Apr 07, 2025

12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga

Apr 07, 2025

Analysts Issue Forecasts for FBRX Q2 Earnings - Defense World

Apr 07, 2025

Equities Analysts Offer Predictions for FBRX FY2025 Earnings - Defense World

Apr 07, 2025

Apr 06, 2025

(FBRX) Investment Analysis - news.stocktradersdaily.com

Apr 06, 2025

Apr 04, 2025

All You Need to Know About Forte Biosciences (FBRX) Rating Upgrade to Buy - MSN

Apr 04, 2025

Forte Biosciences (NASDAQ:FBRX) Given New $61.00 Price Target at Chardan Capital - The AM Reporter

Apr 04, 2025

Apr 03, 2025

Forte Biosciences Sees Unusually Large Options Volume (NASDAQ:FBRX) - Defense World

Apr 03, 2025

Chardan Capital Issues Pessimistic Forecast for Forte Biosciences (NASDAQ:FBRX) Stock Price - Defense World

Apr 03, 2025

Apr 02, 2025

Chardan Adjusts Price Target on Forte Biosciences to $61 From $64, Maintains Buy Rating - MarketScreener

Apr 02, 2025

Forte Biosciences Reports 2024 Progress and Financials - TipRanks

Apr 02, 2025

Apr 01, 2025

Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans? - Yahoo

Apr 01, 2025

Mar 31, 2025

Forte's Celiac Treatment Shows Promise: Zero Dropouts and $58.4M War Chest - Stock Titan

Mar 31, 2025

Forte Biosciences, Inc. Announces Results and Provides Clinical Update - Bluefield Daily Telegraph

Mar 31, 2025

Mar 28, 2025

Forte Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 28, 2025

Forte Biosciences Inc Files For Mixed Shelf Of Up To $300 MillionSEC Filing - MarketScreener

Mar 28, 2025

Forte Biosciences, Inc. SEC 10-K Report - TradingView

Mar 28, 2025